Advanced Cell Technology, Inc. announced that chairman and CEO Gary Rabin will be presenting at the World Stem Cells and Regenerative Medicine Conference, May 21-23, in London. Mr. Rabin's presentation, titled “Successes and ongoing advancements of human clinical trials for the treatment of AMD & Stargardt's Disease,” will be given on Monday, May 21 at 5:05 p.m. BST (London time). Mr. Rabin will provide an update on ACT's three ongoing human clinical trials in the U.S. and E.U. for Dry Age-Related Macular Degeneration (Dry AMD) and Stargardt's Macular Dystrophy (SMD).
ACT recently announced Data and Safety Monitoring Board (DSMB) approval to move forward with enrollment and treatment of additional patients with SMD in its U.S. SMD trial, and to treat the final two patients to round out the initial dosing arm in its European trial. All three of the company's ongoing clinical trials use human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells.